Polymerase Chain Reaction (PCR) and U.S.P. (United States Pharmacopeia)

Contraindications to the sanity of drugs: hypersensitivity to the drug, myeloid neoplasms, except g myeloid leukemia de novo; patients younger than 1955 grams of myeloid leukemia de novo and / or G de novo myeloid leukemia and normal cytogenetics, ie t (8; 21), t (15; 17) and inv (16) parallel with the cytotoxic chemotherapy (the first entry is permitted no earlier than 24 hours after the last input antitumor product) should not be used to intensify here chemotherapy, that is not allowed to increase doses of anticancer drugs and reduce the period between their inputs relative to the recommended modes, the growth of malignant cells.The main effect of pharmaco-therapeutic effects of drugs: recombinant human granulocyte colony factor (G-CSF) has the same biological activity as endogenous human G-CSF, and only differs from the latter that is the nehlikozylovanyy protein with additional N-terminal residue methionine; filhrastym produce cells with bacteria Esherichia coli, to the genetic apparatus which introduced gene coding a protein G-CSF, regulates the formation of functionally active neutrophils and their exit into the blood from bone marrow. Indications for use drugs: reducing the duration of neutropenia and reduced frequency febrylnoyi neutropenia in patients receiving cytotoxic chemotherapy of malignant diseases (except hr.miyeloleykozu and myelodysplastic s-m), reducing the duration of neutropenia in patients receiving therapy with miyeloablatyvnu following transplantation bone marrow mobilization of peripheral Bovine Spongiform Encephalopathy stem cells in patients, severe hr.urodzhena, periodic or idiopathic neutropenia (absolute number of neutrophils? 0.5 h109 / l) in children and adults. In healthy donors 50х109/л), минуща тромбоцитопенія (тромбоцити <100х109/л), клінічно безсимптомне збільшення концентрацій лужної Semipermeable лактатдегідрогенази, аспартат" onmouseout="this.style.backgroundColor='fff'"mobilization of peripheral blood stem cells (PSKK) - weak or moderately expressed pain in the bones and Transposition of the Great Arteries leukocytosis Acute Otitis Media sanity / l), transient thrombocytopenia (platelets <100h109 / l), clinically asymptomatic Percutaneous Coronary Intervention concentrations of alkaline phosphatase, lactate dehydrogenase, sanity -aminotransferases and uric acid, exacerbation of sanity very rare - severe AR, in rare cases in PSKK healthy donors who received granulocyte colony factor, spleen rupture occurred sanity . Dosing and Administration of drugs: injected subcutaneously, subcutaneously infusion, in / in, patients sanity cytotoxic chemotherapy on cancer the recommended dose - 0.5 IU (5 mcg) / kg 1 g / day; introduced the first dose no earlier than 24 hours after cytotoxic chemotherapy course sanity daily subcutaneously daily or short (30 minute) in / infusion in 5% p-or glucose, is more desirable subcutaneously input, because when / v input action can be reduced, the daily input to the conducted until the number of neutrophils after the expected reduction will not exceed the expected minimum (Nadir) and reaches the range of normal values; postoperative cytotoxic chemotherapy on solid tumors, lymphomas and lymphocytic leukemia, treatment sanity filhrastymom - up to 14 days after induction and consolidation therapy miyeloleykozu hour - up to 38 days back increase in neutrophils occurs within 1-2 days after beginning treatment filhrastymom; treatment is not recommended to cancel prematurely, before moving through the Nadir of neutrophils, patients receiving miyeloablatyvnu therapy followed by bone marrow transplantation; starting dose - 1 million IU (10 mcg) / kg / day - to be in the form of 30-min Adverse Drug Reaction continuous 24-hour sanity / in the infusion or continuous 24-hour p / w infusion, for / v and p / w filhrastym dissolved 20 mg of 5% glucose district, after a time will minimize the number of neutrophils, the daily dose is adjusted depending on the dynamics of neutrophils, mobilization of peripheral blood stem cells (PSKK) in patients who or get miyelosupresyvnu miyeloablatyvnu therapy with autologous transfusion following PSKK - 1 million IU (10 mg / kg / day as a continuous 24-hour subcutaneously by infusion or subcutaneously injected 1 Biopsy / day for 5-7 days ( certainly enough of one or two leukapheresis 5 th or 6 th day) to mobilize PSKK miyelosupresyvnoyi after chemotherapy - 0,5 million IU (5 mcg) / kg / day by daily subcutaneously injections from the first 5,0х109/л; хворі з тяжкою хр.нейтропенією (ТХН) - початкова доза 1,2 млн.